17 Aug Increased risk of thrombo-embolic events in patients with anti-phopholipid syndrome (APS) treated with Eliquis
Posted at 12:49h in
Pfizer Laboratories (Pty) Ltd, in agreement with South African Health Products Regulatory Authority (SAHPRA), would like to inform you of the following changes to the Professional Information of Eliquis (apixaban).
Download latest version
Document Number: DHCPL
Date Updated: 13/09/2019
File Type: pdf
Category: Communication To Health Care Professionals